IRLAB: Pirepemat phase IIb study did not meet its primary endpoint - Redeye

Redeye comments on the disappointing news that IRLAB’s drug candidate Pirepemat did not meet its primary endpoint in its phase IIb study targeting PD-fall, which led to a significant sell-off in the share yesterday. We give an initial take but will soon return with an updated valuation where we expect to lower our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1087084/irlab-pirepemat-phase-iib-study-did-not-meet-its-primary-endpoint?utm_source=finwire&utm_medium=RSS